ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Can-Fite BioPharma enrols first patient to study Covid-19 drug
March 09, 2021Can-Fite BioPharma has enrolled the first patient in a Phase II study of its drug, Piclidenoson, to treat hospitalised patients with moderate to severe Covid-19. -
Can-Fite announces pre-IND submission to US FDA for Piclidenoson in treatment of Covid-19 infected p
May 21, 2020Can-Fite BioPharma announced it has filed a pre-Investigational New Drug (IND) meeting request with the U.S. Food and Drug Administration (FDA) for its drug candidate Piclidenoson in the treatment of COVID-19 patients with moderate-to-severe symptoms.
Pharma Sources Insight January 2025
